ArticlePharmacogenomics and personalized medicine2026
Clinical Outcomes of an ApoE Genotype-Guided Lipid-Lowering Strategy in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention.
Article in Pharmacogenomics and personalized medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the clinical efficacy of a statin therapy strategy guided by Apolipoprotein E (ApoE) gene polymorphism in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Patients and Methods: In this retrospective study, 263 ACS patients post-PCI were included. The control group (n=120) received standard atorvastatin therapy. The study group (n=143) received a genotype-guided strategy: patients with ApoE E2/E3 genotypes received atorvastatin monotherapy, while those with the E4 genotype received atorvastatin combined with the PCSK9 inhibitor evolocumab. Clinical efficacy, cardiac function parameters, lipid profiles, and quality of life were compared between groups at 1 and 3 months post-treatment. Results: The total effective rate, defined as the combined proportion of patients rated "markedly effective" (complete symptom resolution with a ≥2-grade improvement in New York Heart Association [NYHA] functional class) and "effective" (notable symptom improvement with a 1-grade NYHA improvement), was significantly higher in the genotype-guided group than in the control group (92.3% vs 82.5%; P=0.025). At follow-up, the study group showed greater improvements in left ventricular ejection fraction (LVEF) and quality of life scores, and greater reductions in left ventricular dimensions and lipid parameters (including LDL-C) (all P<0.05). Multivariate logistic regression analysis identified the genotype-guided treatment strategy as an independent protective factor for clinical efficacy (P<0.05). Conclusion: An ApoE genotype-guided lipid-lowering escalation strategy, in which E4 carriers-who typically respond suboptimally to statin monotherapy and carry a higher residual risk-received add-on PCSK9-inhibitor (evolocumab) therapy, was associated with improved clinical efficacy, cardiac function, and lipid control in ACS patients after PCI. Because the study group received more intensive lipid-lowering therapy, the observed benefits most plausibly reflect the greater treatment intensity achieved through genotype-directed escalation rather than the act of genotyping alone, and require confirmation in prospective randomized trials with longer follow-up.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.